文献速递临床试验与 GCP

机器人辅助立体定向毁损术治疗局灶性药物难治性癫痫的多中心随机对照试验方案

Protocol of a prospective multicenter randomized controlled trial of robot-assisted stereotactic lesioning in the treatment of focal drug-resistant epilepsy.
PubMed 文献 · Trials · 2023-06-09

本方案描述一项多中心三臂随机对照试验,比较射频热凝、激光间质热疗与致痫灶切除术治疗局灶性药物难治性癫痫的安全性和有效性。研究对象为年龄大于3岁、药物难治性发作至少2年且经多学科评估适合手术的局灶性癫痫患者,主要结局为治疗后3个月、6个月和1年的癫痫缓解率。

要点

  • 射频热凝和激光间质热疗为微创手术,癫痫无发作可能性较低但神经功能保护更好。
  • 主要结局为治疗后3个月、6个月和1年随访的癫痫缓解率。
  • 次要结局包括术后神经功能损伤、视频脑电图频谱分布变化、生活质量和医疗费用。

核心结论

  • 本研究旨在比较射频热凝、激光间质热疗与致痫灶切除术治疗局灶性药物难治性癫痫的安全性和有效性。

研究设计与样本

  • 多中心三臂随机对照临床试验。
  • 纳入年龄大于3岁、药物难治性发作至少2年、经随机化前多学科评估确定存在致痫灶且适合手术的癫痫患者。

主要发现

  • 主要结局指标为治疗后3个月、6个月和1年随访时的癫痫结局(以癫痫缓解率量化)。
  • 次要结局包括术后神经功能损伤、视频脑电图频谱分布变化、生活质量和医疗费用。
  • 致痫灶切除术仍是此类局灶性癫痫最常用的治疗,但越来越多证据表明其可能导致神经功能损害。
  • 射频热凝和激光间质热疗实现癫痫无发作的可能性较低,但神经功能保护更好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This protocol describes the design of a multicenter randomized controlled trial of robot-assisted stereotactic lesioning versus epileptogenic foci resection. Typical causes of focal epilepsy include hippocampal sclerosis and focal cortical dysplasia. These patients usually present with drug resistance and require surgical treatment. Although epileptogenic foci resection is still the most commonly used treatment for such focal epilepsy, there is increasing evidence that epileptogenic focus resection may lead to neurological impairment. The treatment of epilepsy with a robot-assisted stereotactic lesioning mainly includes two new minimally invasive surgical methods: radiofrequency thermocoagulation (RF-TC) and laser interstitial thermal therapy (LITT). Seizure-free is less likely to be achieved by these two procedures, but neurologic preservation is better. In this study, we aimed to compare the safety and efficacy of RF-TC, LITT, and epileptogenic foci resection for focal drug-resistant epilepsy. METHODS: This is a multicenter, three-arm, randomized controlled clinical trial. The study will include patients older than 3 years of age with epilepsy who have had medically refractory seizures for at least 2 years and are eligible for surgical treatment with an epileptogenic focus as determined by multidisciplinary evaluation prior to randomization. The primary outcome measure is seizure outcome (quantified by seizure remission rate) at 3-month, 6-month, and 1-year follow-up after treatment. Postoperative neurologic impairment, spectrum distribution change of video electroencephalogram, quality of life, and medical costs will also be assessed as secondary outcomes. TRIAL REGISTRATION: Chinese Clinical Trials Registry ChiCTR2200060974. Registered on June 14, 2022. The status of the trial is recruiting, and the estimated study completion date is December 31, 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gong M, Xu K, Shan Y, et al. Protocol of a prospective multicenter randomized controlled trial of robot-assisted stereotactic lesioning in the treatment of focal drug-resistant epilepsy. Trials. 2023. PMID: 37296479. doi:10.1186/s13063-023-07334-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。